GenSight Biologics S.A. (EPA:SIGHT)
France · Delayed Price · Currency is EUR 0.0995
-0.0005 (-0.50%)
Jan 9, 2026, 5:35 PM CET
GenSight Biologics Revenue
GenSight Biologics had revenue of 48.00K EUR in the half year ending June 30, 2025, a decrease of -98.23%. This brings the company's revenue in the last twelve months to 945.00K, down -52.18% year-over-year. In the year 2024, GenSight Biologics had annual revenue of 2.63M, down -11.44%.
Revenue (ttm)
945.00K
Revenue Growth
-52.18%
P/S Ratio
23.22
Revenue / Employee
72.69K
Employees
16
Market Cap
21.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.63M | -339.00K | -11.44% |
| Dec 31, 2023 | 2.96M | -1.90M | -39.08% |
| Dec 31, 2022 | 4.87M | -2.84M | -36.89% |
| Dec 31, 2021 | 7.71M | 269.00K | 3.62% |
| Dec 31, 2020 | 7.44M | 2.53M | 51.53% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| Ramsay Générale de Santé | 5.24B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
GenSight Biologics News
- 1 day ago - GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates - Business Wire
- 2 days ago - GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2.9 Million • news - Onvista
- 18 days ago - GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel - Business Wire
- 19 days ago - GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France - Business Wire
- 5 weeks ago - GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France - Business Wire
- 2 months ago - GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2 Million • news - Onvista
- 2 months ago - GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US - Business Wire
- 3 months ago - GenSight Biologics Reports Cash Position as of September 30, 2025 - Business Wire